Evidence map›Paper›PMID 41945787›Full record

ArticleAnalytical chemistry2026

A Prototype timsOmni Platform Enables Confident Annotation of the Key Hypervariable CDR3 Regions of IgG Immunoglobulins Using Low- and High-Energy Electron-Based Fragmentation.

Simon Ollivier, Dina Schuster, Danique M H van Rijswijck, Iuliia Stroganova, Athanasios Smyrnakis, Jan Fiala, Mariangela Kosmopoulou, Detlev Suckau, Stuart Pengelley, Oliver Raether and 3 more

Abstract read
In one paragraph

Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simon OllivierBiomolecular Mass Spectrometry & Proteomics, Bijvoet Center for Biomolecular Research & Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.ORCID 0000-0002-7671-1736
Dina SchusterBiomolecular Mass Spectrometry & Proteomics, Bijvoet Center for Biomolecular Research & Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.ORCID 0000-0001-6611-8237
Danique M H van RijswijckBiomolecular Mass Spectrometry & Proteomics, Bijvoet Center for Biomolecular Research & Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.ORCID 0000-0003-1377-9992
Iuliia StroganovaBiomolecular Mass Spectrometry & Proteomics, Bijvoet Center for Biomolecular Research & Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Athanasios SmyrnakisFasmatech Science & Technology, 15232 Athens, Greece.ORCID 0000-0003-1677-4214
Jan FialaBiomolecular Mass Spectrometry & Proteomics, Bijvoet Center for Biomolecular Research & Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Mariangela KosmopoulouFasmatech Science & Technology, 15232 Athens, Greece.
Detlev SuckauBruker Daltonics GmbH & Co. KG, Fahrenheitstrasse 4, 28359 Bremen, Germany.ORCID 0000-0002-1859-2492
Stuart PengelleyBruker Daltonics GmbH & Co. KG, Fahrenheitstrasse 4, 28359 Bremen, Germany.ORCID 0000-0003-2676-8096
Oliver RaetherBruker Daltonics GmbH & Co. KG, Fahrenheitstrasse 4, 28359 Bremen, Germany.
Jean-François GreischBruker Switzerland AG, Industriestrasse 26, Fällanden, 8117 Zurich, Switzerland.
Dimitris PapanastasiouFasmatech Science & Technology, 15232 Athens, Greece.ORCID 0000-0003-2299-9479
Albert J R HeckBiomolecular Mass Spectrometry & Proteomics, Bijvoet Center for Biomolecular Research & Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.ORCID 0000-0002-2405-4404

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The configuration of the first prototype timsOmni instrument, which integrates an Omnitrap linear ion trap into a timsTOF platform, is presented. A modified electrode design for the electron-based fragmentation (ExD) section of the Omnitrap is described, enhancing both the robustness and performance. Optimal characterization of antibodies requires characterizing light and heavy chains as pairs in addition to sequencing their variable domains and identifying any modifications. This is best addressed using protein-centric proteomics, as heterogeneity information such as the specific clonal origin of each identified fragment can be retained. Furthermore, by acting on intact proteins that retain part of their structure, such as disulfide bonds, it is possible to target key regions for fragmentation such as the hypervariable complementarity determining regions (CDR3) that are unique for each clone and necessary for target recognition. Therefore, as a proof of concept, we used the prototype timsOmni mass spectrometer for antibody analysis. Using solely electron-based fragmentation methods, we obtained full CDR3 sequences for paired heavy and light chains. Optimal results were achieved by performing Electron Induced Dissociation (EID) at ∼35 eV electron energy on native-like fragment antigen-binding (Fab) precursor ions. This approach yields both (a, x) and (c, z) fragment ion pairs with the potential to enhance both sequence coverage and annotation confidence. Overall, the timsOmni mass spectrometer presented here serves as an advanced and versatile platform for protein-centric proteomics.

Indexed as

Complementarity Determining RegionsElectronsImmunoglobulin GAmino Acid SequenceHumansMass SpectrometryComplementarity Determining RegionsImmunoglobulin G

Identifiers

PMID41945787
PMCPMC13103932

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.